ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine DLA-Mismatch Model

B. Swearingen1, S. Graves2, R. Storb2, D. W. Mathes1

1University of Colorado School of Medicine, Aurora, CO, 2Fred Hutchinson Cancer Research Center, Seattle, WA

Meeting: 2019 American Transplant Congress

Abstract number: A70

Keywords: Engraftment, Graft acceptance, Stem cells, Tolerance

Session Information

Date: Saturday, June 1, 2019

Session Name: Poster Session A: Basic & Clinical Science – VCA

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall C & D

Related Abstracts
  • AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine Model
  • A Clinically Relevant Protocol for Vascularized Composite Allotransplantation Using a Single Dose of AMD3100 for Stem Cell Mobilization.

*Purpose: Vascularized Composite Allograft (VCA) transplantation is a clinical reality but limited by toxicities of chronic immunosuppression and rejection. Current clinical tolerance protocols rely on recipient conditioning and donor cell mobilization that limits use to living donor transplants. We sought to design a clinically relevant protocol applicable to cadaveric organs. We previously demonstrated that using AMD3100 (Plerixafor) as a single dose agent for stem cell mobilization was successful in a DLA-haploidentical model. We wanted to increase clinical relevance by testing our existing non-myeloablative stem cell canine VCA transplant model to DLA-mismatched, unrelated canine donor-recipient pairs.

*Methods: Three DLA-mismatched, unrelated canine recipients [Group I] received conditioning with 450cGy TBI, AMD3100-mobilized donor stem cells + Bone Marrow (BM) infusion and simultaneous VCA transplantation with a short course of immunosuppression (Sirolimus: 28 days/MMF: 56 days/CSP: 70 days). Three DLA-mismatched, unrelated canine recipient [Group II] underwent a less intense conditioning regimen (350cGy TBI) but otherwise identical transplantation protocol. CD34+ hematopoietic progenitor cells were quantified via flow cytometry. Peripheral blood chimerism was evaluated by PCR techniques weekly. VCA graft survival was followed clinically and histologically.

*Results: All six canines tolerated the conditioning regimen. Stem cell engraftment and donor chimerism was seen in all dogs. Mean COBE apheresis count was 4.28×10^8 cells/kg and mean BM aspirate count was 0.81×10^8 cells/kg across both groups. Outcomes varied. No evidence of acute rejection was seen. Two dogs demonstrated signs of VCA rejection once off immunosuppression. GVHD (skin and/or liver) was seen in two dogs. Two dogs were lost post-operatively to the unexpected complication of intussusception while still seemingly tolerant to the VCA.

*Conclusions: This study demonstrates proof of principle for AMD3100 as a single-dose stem cell mobilizing agent for a clinically relevant tolerance protocol in mismatched, unrelated donor-recipient pairs. Use of AMD3100 led to stem cell engraftment in all animals transplanted with no evidence of acute rejection in the VCA. AMD3100 use limited by thrombocytopenia in our previous studies continue to appear be resolved with the addition of BM Aspirate in this model. Continued experiments should allow for longer-term follow up in future canine recipients that should optimistically not experience bowel complications or GVHD.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Swearingen B, Graves S, Storb R, Mathes DW. AMD3100 (Plerixafor) as a Single-Dose Stem Cell Mobilizing Agent in Vascularized Composite Tissue Allograft (VCA) Transplantation in a Canine DLA-Mismatch Model [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/amd3100-plerixafor-as-a-single-dose-stem-cell-mobilizing-agent-in-vascularized-composite-tissue-allograft-vca-transplantation-in-a-canine-dla-mismatch-model/. Accessed December 8, 2019.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2019 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

wiley-new-logo

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.